Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.

ScFv-h3D6 has been shown as an efficient therapy in the 3xTg-AD mouse model of Alzheimer's Disease. Because one of the major bottlenecks for the therapeutic uses of proteins produced in Escherichia coli is their potential contamination with endotoxins, LPS were extensively removed by a rather l...

Full description

Bibliographic Details
Main Authors: Laia Montoliu-Gaya, Gisela Esquerda-Canals, Silvia Bronsoms, Sandra Villegas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181480&type=printable
_version_ 1826578834283036672
author Laia Montoliu-Gaya
Gisela Esquerda-Canals
Silvia Bronsoms
Sandra Villegas
author_facet Laia Montoliu-Gaya
Gisela Esquerda-Canals
Silvia Bronsoms
Sandra Villegas
author_sort Laia Montoliu-Gaya
collection DOAJ
description ScFv-h3D6 has been shown as an efficient therapy in the 3xTg-AD mouse model of Alzheimer's Disease. Because one of the major bottlenecks for the therapeutic uses of proteins produced in Escherichia coli is their potential contamination with endotoxins, LPS were extensively removed by a rather low-efficient, expensive, and time-consuming purification step. In addition, disulfide scrambling is favored in the reducing bacterial cytoplasm albeit the use of reductase deficient strains. To overcome these hurdles, as well as to improve the yield, the yeast Pichia pastoris, an endotoxin-free host system for recombinant protein production, has been used to produce scFv-h3D6, both in flask and in a fed-batch bioreactor. Comparison of the thermal stability of the obtained protein with that from E. coli showed no differences. Opposite to the case of the protein obtained from E. coli, no disulfide scrambled conformations or LPS traces were detected in that produced in P. pastoris. Cytotoxicity assays in SH-SY5Y neuroblastoma cell-cultures demonstrated that proteins from both expression systems were similarly efficient in precluding Aβ-induced toxicity. Finally, the 3xTg-AD mouse model was used to test the therapeutic effect of both proteins. Quantification of Aβ levels from cortex and hippocampus protein extracts by ELISA, and Aβ-immunohistochemistry, showed that both proteins reduced Aβ burden. This work demonstrates that scFv-h3D6 obtained from P. pastoris shows the same benefits as those already known for that obtained from E. coli, with multiple advantages in terms of recombinant production and safety.
first_indexed 2024-12-13T07:40:58Z
format Article
id doaj.art-a26eeba061fa46059325883491a6aa5c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2025-03-14T14:08:41Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a26eeba061fa46059325883491a6aa5c2025-02-27T05:38:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01128e018148010.1371/journal.pone.0181480Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.Laia Montoliu-GayaGisela Esquerda-CanalsSilvia BronsomsSandra VillegasScFv-h3D6 has been shown as an efficient therapy in the 3xTg-AD mouse model of Alzheimer's Disease. Because one of the major bottlenecks for the therapeutic uses of proteins produced in Escherichia coli is their potential contamination with endotoxins, LPS were extensively removed by a rather low-efficient, expensive, and time-consuming purification step. In addition, disulfide scrambling is favored in the reducing bacterial cytoplasm albeit the use of reductase deficient strains. To overcome these hurdles, as well as to improve the yield, the yeast Pichia pastoris, an endotoxin-free host system for recombinant protein production, has been used to produce scFv-h3D6, both in flask and in a fed-batch bioreactor. Comparison of the thermal stability of the obtained protein with that from E. coli showed no differences. Opposite to the case of the protein obtained from E. coli, no disulfide scrambled conformations or LPS traces were detected in that produced in P. pastoris. Cytotoxicity assays in SH-SY5Y neuroblastoma cell-cultures demonstrated that proteins from both expression systems were similarly efficient in precluding Aβ-induced toxicity. Finally, the 3xTg-AD mouse model was used to test the therapeutic effect of both proteins. Quantification of Aβ levels from cortex and hippocampus protein extracts by ELISA, and Aβ-immunohistochemistry, showed that both proteins reduced Aβ burden. This work demonstrates that scFv-h3D6 obtained from P. pastoris shows the same benefits as those already known for that obtained from E. coli, with multiple advantages in terms of recombinant production and safety.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181480&type=printable
spellingShingle Laia Montoliu-Gaya
Gisela Esquerda-Canals
Silvia Bronsoms
Sandra Villegas
Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
PLoS ONE
title Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
title_full Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
title_fullStr Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
title_full_unstemmed Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
title_short Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
title_sort production of an anti aβ antibody fragment in pichia pastoris and in vitro and in vivo validation of its therapeutic effect
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181480&type=printable
work_keys_str_mv AT laiamontoliugaya productionofanantiabantibodyfragmentinpichiapastorisandinvitroandinvivovalidationofitstherapeuticeffect
AT giselaesquerdacanals productionofanantiabantibodyfragmentinpichiapastorisandinvitroandinvivovalidationofitstherapeuticeffect
AT silviabronsoms productionofanantiabantibodyfragmentinpichiapastorisandinvitroandinvivovalidationofitstherapeuticeffect
AT sandravillegas productionofanantiabantibodyfragmentinpichiapastorisandinvitroandinvivovalidationofitstherapeuticeffect